Arkaya Cosmopharma Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
- Paid Up Capital ₹ 1.00 M
- Company Age 6 Year, 9 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 7.00 M
- Revenue Growth %
- Profit Growth -93.26%
- Ebitda 25.28%
- Net Worth -92.16%
- Total Assets 22.49%
About Arkaya Cosmopharma
Arkaya Cosmopharma Private Limited (ACPL) is a Private Limited Indian Non-Government Company incorporated in India on 15 May 2018 (Six years and nine months 3 days old ). Its registered office is in Nashik, Maharashtra, India.
The Corporate was formerly known as Arkaya Cosmetics Private Limited. The Company is engaged in the Fmcg Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 1.00 M.
The company currently has active open charges totaling ₹7.00 M.
Chandan Gadikar, Kedar Gadikar, and Mahesh Borade serve as directors at the Company.
Company Details
-
Location
Nashik, Maharashtra, India
-
Telephone
+91-XXXXXXXXXX
- Email Address
-
Website
-
-
Social Media
-
Corporate Identity Details
-
CIN/LLPIN
U74999MH2018PTC309434
-
Company No.
309434
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
15 May 2018
-
Date of AGM
30 Sep 2024
-
Date of Balance Sheet
31 Mar 2024
-
Listing Status
Unlisted
-
ROC Code
Roc Mumbai
Industry
Who are the key members and board of directors at Arkaya Cosmopharma?
Board Members (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Kedar Gadikar
|
Director | 15-May-2018 | Current |
|
Chandan Gadikar
|
Director | 20-Sep-2019 | Current |
|
Mahesh Borade
|
Additional Director | 07-Aug-2021 | Current |
Financial Performance of Arkaya Cosmopharma.
Arkaya Cosmopharma Private Limited, for the financial year ended 2023, experienced no change in revenue, with a 0% increase. The company also saw a substantial fall in profitability, with a 93.26% decrease in profit. The company's net worth observed a substantial decline by a decrease of 92.16%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Arkaya Cosmopharma?
In 2023, Arkaya Cosmopharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
₹7.00 M
₹0
Charges Breakdown by Lending Institutions
- Canara Bank : 0.70 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 16 Sep 2021 | Canara Bank | ₹7.00 M | Open |
How Many Employees Work at Arkaya Cosmopharma?
Unlock and access historical data on people associated with Arkaya Cosmopharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Arkaya Cosmopharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Arkaya Cosmopharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
